Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid Naïve ulcerative colitis during active and quiescent disease

Inflammatory Bowel Diseases

Volumn 15, Issue 3, 2009, Pages 328-334

  Matsuda, Reikei ^a   Koide, Tomoko ^b   Tokoro, Chikako ^b   Yamamoto, Tsuyoshi ^a   Godai, Ten'i ^a   Morohashi, Taiki ^c   Fujita, Yuji ^a   Takahashi, Daisuke ^a   Kawana, Ichiro ^b   Suzuki, Shinichiro ^a   Umemura, Satoshi ^d  

^a Fujisawa Shounandai Hospital   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Omori Red Cross Hospital   (Japan)

^d YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Inflammatory cytokines; Inflammatory mucosa; Interleukin 8; Real time PCR; Steroid naive patients; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MESALAZINE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CYTAPHERESIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; GRANULOCYTAPHERESIS; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; LAMINA PROPRIA; MALE; MONONUCLEAR CELL; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; BIOPSY; BIOSYNTHESIS; COLON; COMPARATIVE STUDY; DOSE RESPONSE; DRUG RESISTANCE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; GRANULOCYTE; INTESTINE MUCOSA; LEUKAPHERESIS; METABOLISM; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; GRANULOCYTES; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; INTESTINAL MUCOSA; LEUKAPHERESIS; MALE; MESALAMINE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 66149152303     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20759     Document Type: Article

References (54)

1. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal microflora but is broken in active inflammatory bowel disease. Clin Exp Immunol. 1995;102:448-455.
2. Allison MC, Dhillon AP, Lewis WG, eds. Inflammatory Bowel Disease. London: Mosby; 1998. p 9-95.
3. MacDermott R. Alterations of mucosal immune system in inflammatory bowel disease. J Gastroenterol. 1996;31:907-916.
4. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol. 1999;34: 66-74.
5. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamn Bowel Dis. 2000;6:21-33.
6. Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200.
7. Tibble JA, Sigthorsson G, Bridger D, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
8. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489-493.
9. Lee A. Whyte M, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol. 1993;54:238-288.
10. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998;22:382-389.
11. Rutgeerts P, Sandborn WJ, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
12. Branningan AE, O'Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock. 2000;13:361-366.
13. Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresisas a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334-1341.
14. Sawa Y, Oshitani N, Adachi K, et al. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med. 2003;11:175-179.
15. Freeman B, Buchman T. Interleukin-1 receptor antagonist as therapy for inflammatory disorders. Exp Opin Biol Ther. 2001;1:301-308.
16. Melgar S, Yeung MMW, Bas A, et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 2003;134:127-137.
17. Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leucocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apheresis. 2005;20:171-184.
18. Saniabadi AR, Hanai H, Bjarnason I, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48-59.
19. Hanai H, Watanabe F, Takeuchi K, et al. Leucocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35.
20. Suzuki Y, Yoshimura N, Saniabadi AR, et al. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49.565-571.
21. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001;16:1-9.
22. Meagher LC, Cousin JM, Seckl JR, et al. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immun. 1996;156:4422-4428.
23. Truelove SC, Richards W. Biopsy studies in ulcerative colitis. Br Med J. 1956;1:1316-1318.
24. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
25. Markova S, Nakamura T, Makimoto H, et al. IL-1beta genotype-related effect of prednisolone on IL-1beta production in human peripheral blood mononuclear cells under acute inflammation. Biol Pharm Bull. 2007;30: 1481-487.
26. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473-1482.
27. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
28. Riddell RH. 1997. Histopathology of ulcerative colitis. In: Inflammatory Bowel Disease. Allan RN, Rhodes JM, Hanauer SB, et al, eds. 3rd ed. New York: Churchill Livingstone; 1997. p 291-309.
29. Tanaka T, Okanobu H, Murakami E, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis. 2008;40:731-736.
30. Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002;97:2821-2828.
31. Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251-257.
32. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44.
33. Kanke K, Nakano,M, Hiraishi H, et al. Clinical evaluation of granulocyte/ monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004;36:811-817.
34. Suzuki Y, Yoshimora N, Saito Y, et al. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci. 2006;51:2031-2038.
35. Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther. 2006;6:453-466.
36. Hanai H. Position of selective leucocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol. 2006;12:7568-7577.
37. Yamamoto T, Saniabadi AR, Maruyama Y, et al. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis. 2007;39:626-633.
38. Hanai H, Iida T, Takeuchi K, et al. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis. 2008;40:433-4340.
39. Bresci G, Parisi G, Bertoni M, et al. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J Gastroenterol. 2006;12: 2201-2204.
40. Kruis W, Steinhagen-Thiessen E, Rofberg R. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol. 2005;28: 7001-7006.
41. Bresci G, Parisi G, Mazzoni A, et al. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis. 2007;39:430-434.
42. Muratov V, Lundahl J, Ulfgren AK, et al. Downregulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int J Colorectal Dis. 2006;21:493-504.
43. Domenech E, Hinojosa J, Esteve-Comas M. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-1352.
44. Maiden L, Takeuchi K, Bjarnason I, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008 (in press).
45. Cohen RD. Treating ulcerative colitis without medications - "Look Mom, No Drugs!" Gastroenterology. 2005;128:235-236.
46. Schwartz D, Ferguson JR. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/ monocyte apheresis. Curr Med Res Opin. 2007;23:2715-2728.
47. Abreu MT, Plevy S, Sands BE, et al. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007;41:874-888.
48. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400-409.
49. Hanai H, Iida T, Watanabe F, et al. Effects of Adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with ulcerative colitis. World J Gastroenterol. 2006;12:3393-3399.
50. Yamamoto T, Saniabadi AR, Umegae S, et al. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamn Bowel Dis. 2006;12:719-726.
51. Hanai H, Watanabe F, Yamada M, et al. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004;99:1532-1538.
52. Mohler KM, Torrance DS, Smith GA, et al. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoximia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-1561.
53. ++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1210-1216.
54. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002; 168:3536-3542.